Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 11 (1997), Issue 1, Pages 83-88
http://dx.doi.org/10.1155/1997/954342
Clinical Gastroenterology

Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID

John H Hegarty,1,8 Lars Halvorsen,2 Bouke P Hazenberg,3 Andrzej Nowak,4 Colin L Smith,5 Alan B Thomson,6 G Vantrappen,7 Ceri J Mckenna,8 and Jane G Mills8

1St Vincent’s Hospital, Dublin, Eire, Ireland
2Sentralsykehuset i, Rogaland, Stavangar, Norway
3Drechtstedenzie-Kenhuis Refaja, Dordrecht, Netherlands
4Klinika Gastroenterologii, AM, Katowice, Poland
5Southampton General Hospital, Southampton, UK
6University of Alberta, Calgary, Alberta, Canada
7Gasthuisberg, Leuven, Belgium
8Glaxo Research and Development Limited, Greenford, UK

Received 31 October 1995; Accepted 25 March 1996

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

John H Hegarty, Lars Halvorsen, Bouke P Hazenberg, et al., “Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID,” Canadian Journal of Gastroenterology, vol. 11, no. 1, pp. 83-88, 1997. doi:10.1155/1997/954342